- Home
- TRX vs AVTX Comparison
TRX vs AVTX Comparison
Compare TRX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- AVTX
- Stock Information
- Founded
- TRX 1990
- AVTX 2011
- Country
- TRX Canada
- AVTX United States
- Employees
- TRX N/A
- AVTX N/A
- Industry
- TRX
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- TRX
- AVTX Health Care
- Exchange
- TRX Nasdaq
- AVTX Nasdaq
- Market Cap
- TRX 228.9M
- AVTX 248.3M
- IPO Year
- TRX N/A
- AVTX 2015
- Fundamental
- Price
- TRX $0.77
- AVTX $17.40
- Analyst Decision
- TRX Strong Buy
- AVTX Strong Buy
- Analyst Count
- TRX 1
- AVTX 9
- Target Price
- TRX $1.10
- AVTX $30.14
- AVG Volume (30 Days)
- TRX 3.6M
- AVTX 450.4K
- Earning Date
- TRX 11-28-2025
- AVTX 11-06-2025
- Dividend Yield
- TRX N/A
- AVTX N/A
- EPS Growth
- TRX N/A
- AVTX N/A
- EPS
- TRX N/A
- AVTX N/A
- Revenue
- TRX $47,731,000.00
- AVTX $441,000.00
- Revenue This Year
- TRX $23.64
- AVTX N/A
- Revenue Next Year
- TRX $51.77
- AVTX N/A
- P/E Ratio
- TRX $677.82
- AVTX N/A
- Revenue Growth
- TRX 29.98
- AVTX N/A
- 52 Week Low
- TRX $0.27
- AVTX $3.39
- 52 Week High
- TRX $0.85
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- TRX 63.36
- AVTX 75.89
- Support Level
- TRX $0.71
- AVTX $13.60
- Resistance Level
- TRX $0.85
- AVTX $15.99
- Average True Range (ATR)
- TRX 0.06
- AVTX 1.32
- MACD
- TRX -0.00
- AVTX 0.18
- Stochastic Oscillator
- TRX 74.14
- AVTX 98.03
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).